Scholarlink

<p>Neuroinflammation is now widely recognized as a key contributor to the initiation and progression of neurodegenerative diseases, particularly Alzheimer’s disease (AD) and Parkinson’s disease (PD). Chronic activation of brain-resident immune cells, including microglia and astrocytes, in response to misfolded protein aggregates such as amyloid-β and tau in AD and α-synuclein in PD, promotes maladaptive immune signaling, sustained cytokine release, and disruption of the blood–brain barrier (BBB). This chronic brain inflammation leads to synaptic dysfunction, neuronal loss and ultimately clinical deterioration. These processes are accompanied by disease-specific factors, such as inflammation of the gut-brain axis in PD and genetic modulators including APOE4, TREM2, and LRRK2. Furthermore, the development of fluid biomarkers together with neuroimaging techniques has improved early detection and monitoring of neuroinflammation leading to personalized therapeutic approaches. Clinical trials targeting microglial phenotypes, cytokine signaling, inflammasome activity, and genetic risk factors are emerging therapeutic strategies. Model limitations and heterogeneity of patients present challenges, but insights into neuroimmune interactions could provide a path forward for disease-modifying strategies. The present review aims to summarize new knowledge about the protective and detrimental aspects of neuroinflammation in AD and PD, providing an analysis on these developing prospects for targeted interventions toward slowing or stopping neurodegeneration.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Neuroinflammation in neurodegenerative diseases: pathogenic pathways and emerging pharmacotherapeutic targets in Alzheimer’s and Parkinson’s disease

  • 期刊论文

  • 发表日期：

    2026年7月7日

查看全文
  • Ravi Ranjan Kumar,
  • Kamaljeet,
  • Sourabh Kosey

摘要

Neuroinflammation is now widely recognized as a key contributor to the initiation and progression of neurodegenerative diseases, particularly Alzheimer’s disease (AD) and Parkinson’s disease (PD). Chronic activation of brain-resident immune cells, including microglia and astrocytes, in response to misfolded protein aggregates such as amyloid-β and tau in AD and α-synuclein in PD, promotes maladaptive immune signaling, sustained cytokine release, and disruption of the blood–brain barrier (BBB). This chronic brain inflammation leads to synaptic dysfunction, neuronal loss and ultimately clinical deterioration. These processes are accompanied by disease-specific factors, such as inflammation of the gut-brain axis in PD and genetic modulators including APOE4, TREM2, and LRRK2. Furthermore, the development of fluid biomarkers together with neuroimaging techniques has improved early detection and monitoring of neuroinflammation leading to personalized therapeutic approaches. Clinical trials targeting microglial phenotypes, cytokine signaling, inflammasome activity, and genetic risk factors are emerging therapeutic strategies. Model limitations and heterogeneity of patients present challenges, but insights into neuroimmune interactions could provide a path forward for disease-modifying strategies. The present review aims to summarize new knowledge about the protective and detrimental aspects of neuroinflammation in AD and PD, providing an analysis on these developing prospects for targeted interventions toward slowing or stopping neurodegeneration.